Dyadic International, Inc. announced Research and Development Collaboration with the Israel Institute - for Biological Research (IIBR) to Combat Emerging Diseases &Threats. The company elighted that IIBR has selected the C1 technology for their project designed to potentially combat against emerging diseases and biological threats by deploying the C1 gene expression platform as a potential game changing technology in Israel. The objective of the program is to enable the production of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies, and in high volumes and low cost. This project will provide Dyadic with a unique opportunity to work with such a renowned organization to integrate the C1 gene expression platform into an end to end product development and manufacturing capability to produce biologics and take one or more of them through the regulatory process. Substantially, the work will be performed at IIBR's laboratories by using in-house resources.